SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果